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Abstract. Herein, polyelectrolyte capsules containing anti-inflammatory drug 
indomethacin were formed using layer-by-layer strategy, which involves alternative deposition 
of oppositely charged polyelectrolytes, such as poly(acrylic acid) and poly(ethyleneimine) (or 
chitosan) onto the drug substrate. Two variants of encapsulation have been implemented: direct 
deposition of polyelectrolytes onto indomethacin dispersed in water at рН 6, and preliminary 
formation of soft matrix by solubilization of indomethacin in micellar solutions of cationic 
surfactants. The inclusion of indomethacin into nanosized polyelectrolyte capsules 
(hydrodynamic diameter of three- and five-layer capsules is 90-180 nm) has given a new form of 
indomethacin with the drug content of 0.20-0.25%, which exceeds its limiting solubility in water 
nearly by the factor of 40. The choice of materials and procedures used for preparation of 
capsules, as well as the number of polyelectrolyte layers that form shell has provided the control 
of the drug release from capsule and resulted in the design of pharmaceutical dosage forms with 
long-lasting effect. 
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1. Introduction 
The development of medicine, pharmacology, and biotechnologies resulted in the growing 
interest in the design of new systems for encapsulation and delivery of drugs. Recent 
investigations showed that the objects of supramolecular chemistry represented by amphiphilic 
compounds and biocompatible polymers can provide background for the design of various types 
of nanocontainers (micelles, nano- and microemulsions, liposomes, polyelectrolyte capsules, and 
others), which can retain drugs and preserve them from adverse environmental factors along with 
their target delivery and long-standing effect [1-9]. These nanocontainers possess several 
advantages, among which following can be highlighted: (1) simplicity and high processability; 
(2) nanoscale range, which provides long-lasting circulation in organism; (3) high affinity to cell 
membranes, (4) microheterogeneous nature of nanosystems, which provides the delivery of both 
hydrophobic and polar molecules; (5) low concentration range of the compounds, which 
determines low toxicity of the systems; and (6) sensitivity to external stimuli, which controls 
drug release. By varying the conditions of synthesis and the structure of building blocks for the 
preparation of nanocontainers, one can optimize their properties assuming the features of a 
particular drug and aims of its further application. 
In this work, we focused on indomethacin, a non-steroidal anti-inflammatory drug, 
possessing analgesic, anti-febrile, and antiaggregatory activity [10,11]. However, its wide 
application is limited because of side effects and poor solubility in water, which decreases its 
bioavailability [12-16]. Considerable attention is devoted to the solution of this problem. For this 
purpose, micellar systems, microemulsions, solid lipid and polymeric particles have been 
explored [17-21]. However, there are still no optimal nanocontainers for indomethacin, which 
completely meet the requirements for drug delivery systems in living organisms, such as high 
loading degree, size of less than 200 nm, controlled release of drug, and low toxicity. 
In our previous studies, in order to increase the solubility of indomethacin, we used 
micellar solutions of non-ionic surfactants approved for medicinal and pharmacological 
applications, as well as solutions of dicationic surfactants [22,23]. On the one hand, the choice of 
dicationic surfactants was due to the fact that there are data on successful use of indomethacin–
cationic surfactant compositions in ophthalmology and dermatology [24-27]. On the other hand, 
low critical micelle concentration (cmc) values and a significant solubilization capacity of 
dicationic surfactants provide their use as cationic agents with a reliable safety, which combine 
high effectiveness and minimum toxic effects. Using surfactant solutions, we increased the 
solubility of indomethacin by more than two orders of magnitude [22,23]; however, this was still 
insufficient to achieve a therapeutically relevant concentration. In addition, micellar systems are 
dynamic and, therefore, they do not have constant composition. 
Analysis of recent publications in addition to our experience [28-33] allowed us to 
conclude that polyelectrolyte micro- and nanocapsules are promising for the design of containers 
for drug delivery. An important advantage of these capsules is the ability to control their 
protective properties and the drug release by the directional screening of the materials for the 
formation of shell, as well as the conditions of their formation and operation. 
To prepare nanocontainers, we chose the layer-by-layer (LbL) technique, involving 
adsorption of oppositely charged polyelectrolytes onto the surface of colloidal particles [34-36]. 
This method is characterized by simplicity, high reproducibility, cost effectiveness, quick nature 
of the process, and the preparation of homogeneous nanosized particles. To design these 
capsules, a broad range of natural (polysaccharides and polypeptides) and synthetic (poly(acrylic 
acid), sodium polystyrene sulfonate, and poly(allylamine hydrochloride)) polyelectrolytes is 
available [37-42]. These features justify the marked advantages of layer-by-layer deposition over 
alternative techniques, e.g. polymerization, coacervation, and so on. There are different 
modifications of the protocols of encapsulation of organic compounds using layer-by-layer 
method. Two of them are the most popular, namely, direct deposition of polyelectrolytes onto 
substrate, which is successfully used only in the case of charged compounds; and the preliminary 
inclusion of the substrate into the sacrificial matrix, which assumes the destruction and removal 
of excipient materials after the formation of polyelectrolyte shell [43-48]. Recently, reports 
appeared on the procedures, which consider the preliminary solubilization of uncharged 
compounds using the micelles of ionic surfactant. The charged surfactant–substrate complex acts 
as a “soft” template, which could be used for layer-by-layer deposition of polyelectrolytes [31-
33, 49].  
In this work, we aimed at the preparation of nanosized polyelectrolyte capsules loaded with 
indomethacin, which provides prolonged release and protects against adverse environmental 
effects. For shell formation, poly(acrylic acid) (PAA) was used as a polyanion, while 
poly(ethylene imine) (PEI) or low-molecular weight chitosan acted as polycations. In this study, 
two variants of the capsules preparation were used: (1) direct deposition of polyelectrolytes onto 
indomethacin dispersed in aqueous solution or (2) the protocol, involving preliminary 
solubilization of indomethacin in micellar solutions of cationic surfactants with the formation of 
a charged indomethacin–surfactant complex. In order to solubilize indomethacin, the following 
cationic surfactants were used: cetyltrimethylammonium bromide (CTAB) and hexamethylene-
1,6-bis(dimethylhexadecylammonium dibromide (16-6-16). Structural formulas of the 
compounds are given below. 
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This work involved the following stages: (1) formation of three-, five-, and seven-layered 
capsules using various modifications of LbL method; (2) evaluation of losses of indomethacin 
during encapsulation; (3) determination of size and surface charge of capsules; (4) evaluation of 
their penetration ability; and (5) determination of the toxicity of drug loaded capsules. 
 
Materials 
Indomethacin with 99% of purity was purchased from Sigma-Aldrich and used as received. 
To form polyelectrolyte capsules, PAA (MW 1800 Da), branched PEI (MW 25000 Da), and low-
molecular weight chitosan (MW 50,000-190,000 Da) (Sigma-Aldrich) were used. To prepare 
micellar solutions, CTAB (Sigma-Aldrich) or dicationic surfactant 16-6-16 were used. 16-6-16 
was synthesized by the reaction of N,N,N',N'-tetramethyl-1,6-hexamethylenediamine with excess 
n-hexadecyl bromide in acetone followed by double recrystallization from ethyl alcohol 
according to the procedure from [50]. Some synthetic details are given in Supporting 
information. 
 
2.2 Preparation of polyelectrolyte capsules 
Polyelectrolyte capsules were formed using layer-by-layer technique using a template composed 
of micellar solutions of cationic surfactants with solubilized indomethacin forming a positively 
charged surfactant/drug complex. In this procedure, 0.0075 g of indomethacin was added into 6 
mL of 1.2∙10-4 mol/L aqueous solution of dicationic surfactant 16-6-16 (when CTAB was used 
its concentration was 3∙10-3 mol/L) and stirred for 30 min at 1000 rpm. Then this mixture was 
centrifuged at 13000 rpm for 13 min and the precipitate was isolated. After that, 8 mL of 1 
mg/mL PAA was added to this precipitate and vigorously stirred for 5 min. The centrifugation 
was repeated and the precipitate was isolated. Similar procedure was used with PEI (or chitosan): 
8 mL of 1 mg/mL polyamine solution was added to the precipitate followed by stirring and 
centrifugation. pH 6-7 was maintained in all solutions during this procedure. The рН of solutions 
was adjusted using HCl or NaOH and it was controlled using a Hanna 213 рН-meter equipped 
with a HI 1330 electrode. Depending on the task, the procedure for deposition of polyelectrolytes 
was repeated and capsules with the specified number of layers were prepared. After deposition of 
the last layer of polyanion, the precipitate was separated and 4 mL of bidistilled water was added 
for further storage and testing of the capsules. 
An alternative procedure for encapsulation of indomethacin was used for direct deposition 
of polyelectrolyte shell onto the dispersed drug. The method for encapsulation is analogous to 
that described above; however, in this case, the polycation layer was deposited first.  In this 
procedure, 0.0075 g of indomethacin was added into 6 mL of water (pH 7) and stirred for 15 min 
at 1000 rpm. After that, 8 mL of 1 mg/mL PEI (or chitosan) was added and vigorously stirred for 
5 min. Then this mixture was centrifuged at 13000 rpm for 15 min and the precipitate was 
isolated. After that, 8 mL of 1 mg/mL PAA was added to this precipitate and vigorously stirred 
for 5 min and precipitate was isolated by centrifugation. The procedure for deposition of 
polyelectrolytes can be repeated and capsules with the specified number of layers were prepared. 
The capsules prepared using this method were positively charged. 
 
2.3 Control of losses of indomethacin during encapsulation 
Losses of indomethacin at each stage of capsule formation were controlled by spectrophotometry 
using Specord 250 Plus spectrophotometer (Germany). For this purpose, solutions remaining 
after the deposition of each polyelectrolyte layer were collected and their absorbance (D) at 327 
nm was determined. The concentration of indomethacin (C) in the supernatant was evaluated 
using Lambert–Beer equation C = D/(ε×L), where ɛ is the molecular absorption coefficient 
corresponding to 5800 mol/(L cm) [22,23], in the case of indomethacin in neutral media and L is 
the optical path length. Then, assuming the volume of filtered solutions, the total content of 
indomethacin was determined and the losses at each stage of capsule formation were evaluated. 
The encapsulation efficiency (ЕЕ,%) and loading capacity (LC) were evaluated from equations: 
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 2.4 Determination of size and charge of capsules  
Sizes and zeta potential of polyelectrolyte capsules were determined using Malvern 
ZetaSizer Nano (Malvern Instruments, UK). The source of laser radiation was a He-Ne gas laser 
with the power of 10 mW and the wavelength of 633 nm. The light scattering angle is 173о. The 
pulse accumulation time is 5-8 min. The signals were analyzed using a single-plate multichannel 
correlator coupled with IBM PC compatible computer equipped with the software package for the 
evaluation of effective hydrodynamic radius of dispersed particles. 
Transmission electron microscopy (TEM) images were obtained on a Hitachi HT7700 
TEM instrument (Japan) operated at 110 kV accelerating voltage. The samples were dispersed 
on 300 mesh copper grids with continuous carbon-formvar support films. 
2.5 Drug release studies 
The release of indomethacin from capsules was studied using dialysis method. To carry 
out these studies, aqueous solution containing capsules with imdomethacin was transferred 
into the dialysis bag with the molecular weight cut-off 40 kDa, which was then immersed 
into the beaker containing a total of 100 mL of phosphate buffer solution (рН 6.86). The 
process was conducted at constant stirring maintaining the temperature of the medium at 
37оС. After particular time intervals, aliquots were taken from the solution and their 
absorbance at 327 nm was measured using spectrophotometer, and the concentration of 
indomethacin (C) was evaluated using Lambert–Beer equation. Using these data, the 
dependence was plotted, which reflects the change in the drug concentration with time. This 
dependence reached a plateau in the end of the drug release from capsules. Each experiment 
was repeated at least 3 times. Experimental data were analized by nonlinear least squares 
regression, using Origin Pro 8.5 software.  
 
2.6 Determination of toxicity of indomethacin loaded into polyelectrolyte capsules  
Investigation of acute toxicity was carried out according to ref [51,52]. In brief, 96 outbred 
male mice weighing 22-24 g and 84 male rats weighing 180 – 220 g were used in these 
experiments. Each dose was administered intraperitoneally and intragastrically to six mice and 
six rats. The mortality rate was observed in all the doses after 24 and 48 hrs. The experiment was 
repeated in triplicates with each concentration. LD50 was calculated by graphical method from 
dependence of percent mortality versus indomethacin concentration. For subsequent verification, 
LD50 values were obtained by graphical methods of Dragstedt-Behrens as given by Carpenter 
[53].  
All experiments involving animals were performed in accordance with the guidelines set by 
the European Communities Council Directive (1997). All in vivo experiments reported in  this 
work were approved by the Ethical Committee of Kazan State Medical University (approval 
number 5 from 28th May 2012). Animals were housed in stainless steel cages, were fed with 
standard multiration pellets for rodents (Effect Ltd., Chapaevsk, Russian Federation), and had  
unlimited access to water. 
 
3. Results and discussion  
3.1. Size and charge of polyelectrolyte capsules loaded with indomethacin 
 
Among various LbL methods, we selected two alternative protocols of shell formation for 
the preparation of polyelectrolyte capsules with encapsulated indomethacin. The first protocol 
involved solubilized form of the drug using micelles of cationic surfactants and the second 
protocol utilized a direct deposition of polyelectrolytes onto the dispersed drug. In the former 
case, the drug/surfactant complex is formed, which has a positive surface charge before 
deposition of the first layer of a polyanion. This enhances electrostatic interactions in the system 
and affects capsule size. As a surfactant, we employed conventional CTAB and its dicationic 
counterpart 16-6-16 characterized by a significantly lower threshold of micelle formation and 
high solubilization capacity [8]. The direct deposition of polyelectrolyte shell onto indomethacin 
was carried out at рН 6-7. Since indomethacin has a рK of 4.5 [54], it is almost completely 
ionised under pH conditions used. In this case, the polycation layer is deposited first and the 
surface of the capsule bears positive charge. 
The number of polyelectrolyte layers was varied from 3 to 7. The scheme of the 
encapsulation of indomethacin involving its prior solubilization in micelles is shown in Fig.1. 
 
Fig.1. Scheme of formation of polyelectrolyte capsules. 
 
Investigation of the properties of capsules involved the determination of their size and 
charge, evaluation of the encapsulation efficiency, and studies of drug release.  
 Using electrophoretic light scattering, electrokinetic potential (-potential) of particles 
was monitored during the encapsulation (Fig.2). These data show the recharging of the system in 
the process of shell formation. The final potential of the particles is shown to be determined by 
the charge of polyelectrolytes and the order of deposition of layers; e.g. in the case of three-layer 
capsules CTAB/PAA/PEI/PAA loaded with indomethacin, -potential is -50 – -55 mV. Sizes of 
the capsules were determined using dynamic light scattering. It was shown that the size 
distribution of capsules is unimodal and is characterized by a polydispersity index of 0.1 - 0.3.  
In the case of three-layered capsules when using micellar solution of CTAB as a template, their 
hydrodynamic diameter is 190±11 nm, while in the case of dicationic surfactant 16-6-16 the 
particle size was smaller (90-110 nm). The particle size increased slightly with an increase in the 
number of layers (Fig. 3); e.g. 5- and 7-layered capsules had their diameter around 120±9 nm 
and 140±10 nm, respectively. 
 
 
Fig.2. Change of zeta-potential of particles during capsule formation. 
 
 
 
Fig.3. Change of hydrodynamic diameter of 16-6-16/PAA/PEI capsules loaded with 
indomethacin after each deposited layer of polyelectrolytes. 
   
 
Fig.4. TEM images of 3-layered capsules 16-6-16/PAA/PEI loaded with indomethacin.  
 
  
Fig.5. TEM images of 5-layered capsules 16-6-16/PAA/PEI loaded with indomethacin. 
 
Images obtained by transmission electron microscopy (Figs. 4,5) demonstrate that capsules 
are spherical. The diameter of particles is 60-100 nm for 3-layered capsules and 120-150 nm for 
5-layered capsules. These results are in good agreement with the DLS data. 
 Using spectrophotometry, the losses of indomethacin during synthesis were evaluated. It 
was determined that losses were 40% when using dicationic surfactant 16-6-16, while in the case 
of CTAB they were greater than 50%. Thus, dicationic surfactant possessing better solubilization 
capacity than its monocationic counterpart provides an increase in the encapsulation efficiency 
and the formation of the particles with a smaller size than in the case of CTAB. The substitution 
of PEI by natural polycation chitosan gave three-layered capsules with the hydrodynamic 
diameter of 105±12 nm; in this case, losses of indomethacin during synthesis were around 50%. 
Through the alternating PEI/PAA (or chitosan/PAA) deposition directly onto dispersed 
indomethacin, three-layered positively charged capsules are formed, with a zeta potential of 65-
70 mV and hydrodynamic diameter of 170-180 nm and losses of preparation upon the LbL 
process of ca. 50-60%. Thus, by varying the conditions of capsule preparation, one can prepare 
nanosized polyelectrolyte capsules loaded with indomethacin with various surface charges. This 
can be an essential factor determining mucoadhesive properties of the pharmaceutical form of 
indomethacin [55]. 
An important aspect of the preparation of capsules is their loading capacity. For this reason, 
a series of experiments were carried out, where the ratio and concentration of surfactant and 
indomethacin were varied upon the formation of micellar template. The main problem was the 
precipitation of free indomethacin during this procedure. Maximum loading was obtained under 
the conditions described in Experimental section when using dicationic surfactant 16-6-16; in 
this case, nanosized polyelectrolyte capsules with 0.20-0.25% of loaded indomethacin were 
prepared, which is nearly 40 times as high as its maximum solubility in water. 
 
3.2 Release of indomethacin from polyelectrolyte capsules 
An important feature of polyelectrolyte capsules is their ability for a gradual drug release. 
This process was controlled by dialysis followed by spectrophotometric determination of the 
concentration of drug released. We adopted the procedure, which was suggested for 
determination of the release of indomethacin from polyelectrolyte films [17] using a phosphate 
buffer (рН 6.86) as a receiving medium atat 37 оС. In addition, we varied pH of medium in some 
experiments in order to evaluate the impact of this factor on the penetration ability of the capsule 
shell. In addition, we varied pH of medium in some experiments in order to evaluate the impact 
of this factor on the penetration ability of the capsule shell in vitro. 
Fig.6 illustrates the changes in the absorption spectra of the dialysate solutions with time 
resulting from the release of indomethacin from capsules into the bulk medium. An increase in 
the absorbance of the solution at maximum (Figs.7 and 8) reflects the release of indomethacin, 
which depends on the nature of polyelectrolytes, the order and the number of deposited layers, as 
well as the contribution of electrostatic interactions between layers controlled by the change of 
рН. Some average characteristics of the capsules obtained from several independent 
experiments, are given in Table 1. 
 Fig.6. Change in the absorbance of dialysate solutions (indomethacin) with time (three-layered 
capsules based on CTAB/PAA/PEI, 37 оС, pH 7). 
 
Fig.7. Release of free and encapsulated indomethacin from dialysis bag (three-, five-, and seven-
layered capsules 16-6-16/PAA/PEI, 37 оС, pH 7-9). 
 
 
 
Fig.8. Release of indomethacin from three-layered capsules 16-6-16/PAA/chitosan at рН 8 (1), 
рН 7 (2), as well as from the five-layered capsules at рН 7(3) (37 оС). 
 
 
 
Table 1. Size of the polyelectrolyte capsules loaded with indomethacin and drug release 
characteristics.  
Shell Template 
Number 
of layers 
EE,% LС, % Dh, nm рН 
Released 
indomethacin, % 
2 h 5 h 
PAA/PEI CTAB 3 46±5 14±1.5 190±20 7 72±3 89±4 
 
PAA/PEI 
 
16-6-16 
 
3 
 
60±3 
 
17±1 
 
100±10 
7 
8 
9 
66±2 
73±3 
87±4 
80±3 
85±3 
94±4 
PAA/PEI 16-6-16 5 60±3 13±1 120±9 7 47±2 63±3 
PAA/PEI 16-6-16 7 60±3 9±0.8 140±11 7 33±2 46±2 
PAA/Chitosan 16-6-16 3 50±4 15±0.5 105±12 7 24±2 43±3 
PEI/PAA 
Without 
surfactant 
3 55±5 13±1 110±15 7 45±2 74±3 
 
The analysis of the data reveals that the release of encapsulated indomethacin occurs 
significantly slower compared to the permeation of free drug through the dialysis membrane; that 
is, the diffusion of the drug through the shell is a rate-determining step. This observation 
indicates the possibility of using these polyelectrolyte capsules as pharmaceutical forms for drug 
delivery with long-lasting effect. 
The capsules with CTAB as a micellar template were found to be more permeable for 
indomethacin than those prepared with 16-6-16 surfactant. With an increase in the number of 
layers, the permeability of capsules decreases; e.g. the transition from three-layered to seven-
layered capsules slows down this process nearly by two times. The capsules, formed by the 
direct deposition of polyelectrolytes onto indomethacin are slightly less permeable for the drug 
than those, prepared with micellar template. Substitution of PEI by natural polyelectrolyte 
chitosan results in a significant inhibition of the release of indomethacin. For example, 66% of 
indomethacin is released within 2 h in the former case, while in the latter case its release is only 
24% within the same time. 
An important factor responsible for the release of encapsulated substrate is the solution pH: 
the release of indomethacin is facilitated with the growth in pH (Fig.7). This can be rationalized 
by the change in the charge of polyelectrolytes, weakening of binding of macromolecules, and 
softening of shell. It can be suggested that the destruction of capsules would occur at a critical 
pH value and the release of indomethacin would be related to this process. 
In order to evaluate the stability of the capsules loaded with indomethacin, monitoring of 
release processes was accompanied by the determination of particle size. The results obtained by 
dynamic light scattering are given in Fig.9 (a,b), which show that the particle size distribution 
remains unchanged for a long time in the range of рН 5-7 (Fig.9 a). The data obtained at pHs > 
7.5 indicate instability of the system, which increases as the pH rise. To illustrate this, we placed 
the capsules in a solution at pH 9.2. Both larger and smaller aggregates appear with time on the 
diagram of particle distribution at pH 9.2, with polydispersity index increasing and unimodal 
distribution distorted in some cases (Fig.9 b). All this suggests that capsules are partially broken 
and the release of indomethacin is primarily related to this process.  
     
Fig.9. Changes in particle size distributions  of three-layered capsules with time at pH 7 (a), pH 
9.2 (b). 
 
Similar result was obtained in the case of decrease in solution pH. (Fig.S3). For example, 
under pH 4.5, the release of indomethacin from a three-layer capsule is approximately one and a 
half times higher compared to neutral pH due to decrease of contribution of anionic form of 
PAA.  
To study the indometacin release from capsules the kinetic model of Ritger – Peppas [56] 
has been used. This simple semi-empirical model is fully sufficient for spherical delivery 
systems [57-59] and given by equation:    
n
inf
t tk
M
M
1 , 
here Mt  and Minf  are absolute cumulative amounts of drug released at time t and infinite time; k 
is a constant incorporating structural and geometric characteristics of the particles, and n is the 
release exponent, indicative of the mechanism of drug release. In the case of spherical delivery 
systems when n = 0.43 drug release mechanism is Fician diffusion. An n value of 1 corresponds 
to zero-order release kinetics (case II transport); 0.43 < n < 1 means an anomalous (non-Fickian) 
diffusion release model; and n > 1 indicates a super case II transport relaxational release [56]. 
The results obtained by fitting the release data in terms of Peppas equation are summarized in 
Table 2 and Fig. S4. As can be seen n values obtained at pH 7-8 rang mainly around values of 
0.4-0.5, which allows one to assume that the drug release mechanism is Fician diffusion. Values 
of n slightly increase with an increase in the number of layers deposited; they are somewhat 
higher for chitosan based capsules. For PAA/PEI capsules a decrease of n values at pH≥8 can be 
due to the fact that diffusion of drug from capsules is additionally contributed by partial 
desintegration of capsule shells thereby enhancing drug release. In the case of PAA/chitosan 
capsules n value of 0.49 at pH 8 probably testifies that the integrity of capsules is preserved. The 
k values characterizing the diffusion rate depending on the structure of capsules decrease with an 
increase of the number of layers; they are somewhat lower for the chitosan based capsules. The 
latter can be of importance upon the fabrication of drug delivery systems with prolonged 
released of the drug.  
 
Table 2. Parameters obtained upon fitting experimental data (Figs 7,8) to Ritger –Peppas model. 
 
capsule  Number of 
layers 
pH k n 
PAA/PEI 3  9 0.70±0.019 0.26±0.027 
PAA/PEI 3  8 0.57±0.019 0.28±0.030 
PAA/PEI 3  7 0.47±0.025 0.41±0.043 
PAA/PEI 5  7 0.34±0.012 0.42±0.024 
PAA/PEI 7  7 0.23±0.017 0.45±0.046 
PAA/chitosan 3 8 0.25±0.009 0.49±0.016 
PAA/chitosan 3 7 0.18±0.006 0.53±0.015 
PAA/chitosan 5  7 0.01±0.003 0.61±0.015 
 
The potential of in vivo application of indomethacin-loaded polyelectrolyte capsules leads to the 
need to evaluate their safety. For this reason, we investigated acute toxicity of three-layered 
empty and indomethacin-loaded capsules based on poly(acrylic acid)/chitosan. The experiments 
were carried out in mice and rats by intraperitoneal injection (i.p.) and direct intragastric 
administration (Table 3). 
 
 
Table 3. Parameters of acute toxicity of free indomethacin and indomethacin-loaded 
nanocapsules during administration to laboratory animals. 
No. Substance LD50 (mg/kg) 
1 
Indomethacin i.p. to mouse 
19±5  
 
2 Indomethacin i.p. to rat 
21±7 
 
3 Nanocapsules with indomethacin i.p. to mouse 42±7 
4 Nanocapsules with indomethacin i.p. to rat 43±9 
5 Indomethacin intragastrically to mouse 36±6 
6 Indomethacin intragastrically to rat 32±7 
7 
Nanocapsules with indomethacin intragastrically to 
mouse 
70±11 
8 Nanocapsules with indomethacin intragastrically to rat 60±12 
9 
Nanocapsules without indomethacin intragastrically to 
mouse 
Not detected up to  
2000 mg/kg 
10 
Nanocapsules without indomethacin intragastrically to 
rat 
Not detected up to 
3000 mg/kg 
 
Our results on intraperitoneal administration of free indomethacin provided LD50 values of 
19±5 mg/kg (in mice) and 21±7 mg/kg (in rats), which broadly agrees with the literature data 
(13±3 and 15±3 mg/kg, respectively [60]). The empty capsules were found to be nontoxic, with 
lethal doses not detected even at the maximum injected concentration of 2000 mg/kg. The value 
of LD50 (mg/kg) of the capsules containing indomethacin was greater than that for the free drug 
introduced into organism as an aqueous suspension. This result is independent of the route of 
administration, i.e. intraperitoneal injection or intragastric administration, and is reproduced for 
tests both on mice and rats. Capsules prepared in this study may be considered as drug carriers 
alternative to other types of nanocontainers, e.g. indomethacin-loaded polymeric nanoparticles 
prepared from self-assembled amphiphilic N-vinylpyrrolidone, for which LD50 is 50-70 mg/kg 
[54]. Meanwhile, the possibility of tuning the capsule properties by the variation of the number 
and order of layer deposition, including the simple way of the control of drug release provides 
them potential advantage for practical applications.  
 
Conclusions  
Encapsulation protocol has been developed for a model anti-inflammatory drug 
indomethacin using layer-by-layer strategy, which involves the alternating deposition of 
oppositely charged polyelectrolytes, such as poly(acrylic acid) and poly(ethylene imine) (or 
chitosan) onto the drug substrate. Two variants of encapsulation have been implemented: 1) 
direct deposition of polyelectrolytes onto indomethacin dispersed in water at рН 6, which 
assumes the deposition of polycation (PEI) as the first layer. In this case, the particles carrying 
positive charge are obtained (zeta potential is +65-70 mV); 2) preliminary formation of soft 
matrix by solubilization of indomethacin in micellar solutions of cationic surfactants yielding 
the capsules with negative charge on their surface (zeta potential is -50 to -55 mV). The 
hydrodynamic diameter of three- and five-layered capsules is 90-180 nm and losses of 
indomethacin during capsule preparation are ≤50%. 
The inclusion of indomethacin into nanosized polyelectrolyte capsules has resulted in a new 
form of indomethacin with the content of the loaded drug of 0.20-0.25% that exceeds its limiting 
solubility in water nearly by a factor of 40. The choice of materials and procedures used for 
preparation of capsules, as well as the number of polyelectrolyte layers that form capsule shell 
has provided the possibility to control drug release. These capsules are of potential interest for 
design of pharmaceutical forms with long-lasting effects. 
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Fig.1. Scheme of formation of polyelectrolyte capsules. 
 
Fig.2. Change of zeta-potential of particles during capsule formation. 
 
 
 Fig.3. Change of hydrodynamic diameter of 16-6-16/PAA/PEI capsules loaded with 
indomethacin after each deposited layer of polyelectrolytes. 
 
 
Fig.4. TEM images of 3-layered capsules 16-6-16/PAA/PEI loaded with indomethacin.  
 
  
Fig.5. TEM images of 5-layered capsules 16-6-16/PAA/PEI loaded with indomethacin. 
 Fig.6. Change in the absorbance of dialysate solutions (indomethacin) with time (three-layered 
capsules based on CTAB/PAA/PEI, 37 оС, pH 7). 
 
Fig.7. Release of free and encapsulated indomethacin from dialysis bag (three-, five-, and seven-
layered capsules 16-6-16/PAA/PEI, 37 оС, pH 7-9). 
 
 
 
Fig.8. Release of indomethacin from three-layered capsules 16-6-16/PAA/chitosan at рН 8 (1), 
рН 7 (2), as well as from the five-layered capsules at рН 7(3) (37 оС). 
 
 
  
Fig.9. Changes in particle size distributions  of three-layered capsules with time at pH 7 (a), pH 
9.2 (b). 
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The synthesis of hexamethylene-1,6-bis(dimethylhexadecylammonium dibromide (16-6-16) 
16-6-16 was synthesized by the reaction of N,N,N',N'-tetramethyl-1,6-
hexamethylenediamine  (0.01 mol) with excess n-hexadecyl bromide (0.022 mol) in acetone. The 
mixture was stirred in the flask equipped with a reflux condenser for 8 h at 56 оС, then the 
precipitate formed was recrystallized twice from ethyl alcohol. Yield 85%. 
The synthesized compound was characterized by the following data: elemental analysis: for 
C42H90N2Br2 calculated (%): C 64.42, Н 11.58, N 3.57, Br 20.41; found (%): C 64.30,Н 12.13, N 
3.56, Br 20.90; melting temperature of 203–204°С. IR spectrum (КBr), ν/cm–1: 3432, 3006, 
2920, 2852, 1495, 1471, 1396, 985, 946, 925, 785, 724. 1H NMR spectra were recorded by using 
Bruker AVANCE 600 and Bruker AVANCE II 400 instruments. 1H NMR (CDCl3, δ, ppm; J, 
Hz) 0.87 [t, 6Н, 2хN+CH2(CH2)13CH2CH3, J = 6.90]; 1.24-1.33 [br m, 52Н, 
2хN+CH2(CH2)13CH2CH3)]; 1.56 [br s, 4H, 2хN+CH2(CH2)13CH2CH3)]; 1.69 [br m, 4Н, 
N+CH2CH2(CH2)2CH2CН2N+]; 1.96 [br m, 4Н, N+CH2CH2(CH2)2CH2CН2N+]; 3.36 [s, 12Н, 
2хN+(CH3)2]; 3.46 [m, 4Н, 2хN+CH2(CH2)13CH2CH3]; 3.67 [m, 4Н, 
N+CH2CH2(CH2)2CH2CН2N+] 
  
 
 
 
Fig.S1. Scheme of formation of polyelectrolyte capsules by direct deposition of polyelectrolytes 
onto indomethacin dispersed in water 
 
 
 
 
 
Fig.S2. Change of zeta-potential of particles during capsule formation by direct deposition of 
polyelectrolytes onto indomethacin dispersed in water  
 
 
 
 
 Fig. S3. Release encapsulated indomethacin from dialysis bag at different pH (three-layered 
capsules 16-6-16/PAA/PEI, 37 оС) 
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Fig.S3. Release of indomethacin from three-layered capsules PAA/chitosan at рН 8 (1), рН 7 
(2), as well as from the five-layered capsules at рН 7(3) (37 оС). Predicted data from equation 
Ritger –Peppas are given by dashed lines.  
 
 
